SCHEDULE: Access Industries, Clal Maintain 11.56% Stake in MediWound
Beneficial Ownership Amendment
Access Industries and its affiliated entities, including Clal Industries, filed an Amendment No. 6 to Schedule 13D, reaffirming their beneficial ownership of 11.56% of MediWound Ltd.'s ordinary shares.
Summary
- Reporting Persons, including Access Industries Holdings LLC, Access Industries, LLC, Access Industries Management, LLC, Clal Industries Ltd., Clal Biotechnology Industries Ltd., Clal Life Sciences L.P., and Len Blavatnik, filed Amendment No. 6 to Schedule 13D.
- The filing updates their beneficial ownership information in MediWound Ltd. (the "Issuer").
- These Reporting Persons collectively beneficially own 1,481,521 Ordinary Shares, representing 11.56% of MediWound Ltd.'s outstanding shares.
- The percentage is based on an aggregate of 12,821,433 Ordinary Shares issued and outstanding as of September 30, 2025, as set forth in the Issuer's prospectus supplement.
- Clal Biotechnology Industries Ltd. (CBI) directly owns 308,811 Ordinary Shares and may be deemed to share voting and investment power over the 1,172,710 Ordinary Shares owned directly by Clal Life Sciences L.P. (CLS).
- Clal Life Sciences L.P. (CLS) solely beneficially owns 1,172,710 Ordinary Shares, representing 9.15% of the class.
- The filing details a complex control structure where Len Blavatnik ultimately controls Access Industries entities, which in turn control Clal Industries, the controlling shareholder of CBI, which controls CLS.
Sentiment
Score: 6
Explanation: The filing is neutral to slightly positive, indicating stable, significant beneficial ownership by a prominent investment group. It doesn't contain new operational or financial information, but the continued stake suggests ongoing confidence.
Positives
- Continued significant beneficial ownership by a major investment group (Access Industries/Len Blavatnik) and its affiliates, which can signal long-term interest and confidence in MediWound.
- The stable ownership percentage (11.56%) suggests no immediate divestment plans by these significant shareholders.
Industry Context
This filing indicates continued significant institutional and strategic investor interest in MediWound, a biotechnology company. Large beneficial ownership stakes by entities like Access Industries and Clal Industries are common in the biotech sector, often reflecting long-term investment horizons in companies with promising drug pipelines or technologies.
Related Party Transactions
- The filing details a complex, multi-layered control structure where various Access Industries and Clal entities are interconnected and ultimately controlled by Len Blavatnik.
- Clal Biotechnology Industries Ltd. (CBI) and Clal Life Sciences L.P. (CLS) are related parties within this structure, with CBI owning shares directly and sharing power over CLS's shares.
- All Reporting Persons are deemed to share voting and investment power over the shares due to this intricate control chain.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant beneficial ownership, confirming a stable, large institutional stake. This can offer a degree of confidence or stability.
- Management: Awareness of a significant, potentially influential shareholder group.
Key Dates
| Date | Description |
|---|---|
| 2022-03-17 | Initial Schedule 13D filing by Reporting Persons. |
| 2022-07-01 | Amendment No. 1 to Schedule 13D filed. |
| 2022-09-26 | Amendment No. 2 to Schedule 13D filed. |
| 2023-02-13 | Amendment No. 3 to Schedule 13D filed. |
| 2023-09-01 | Amendment No. 4 to Schedule 13D filed, including Joint Filing Agreement (Exhibit 99.2). |
| 2024-07-19 | Amendment No. 5 to Schedule 13D filed. |
| 2025-09-30 | Date of event requiring filing of this statement; also the date of the Issuer's prospectus supplement and the basis for outstanding share count (12,821,433 shares). |
| 2025-10-03 | Filing date of Amendment No. 6 to Schedule 13D. |
Keywords
MediWound Ltd., MWND, Access Industries, Clal Industries, Len Blavatnik, Beneficial Ownership, Schedule 13D, SEC Filing, Biotechnology, Investment, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.